Chinese Promoter Of Fatal Diglycol-Laced Drug Sentenced To Life
This article was originally published in PharmAsia News
A promoter connected with the deaths of 14 Chinese hospital patients given Armillarisni A containing diglycol has been sentenced to life imprisonment. The head of the State FDA at the time of the scandal was executed last July on charges of corruption and dereliction. Wang Guiping was found guilty May 23 of charges of selling fake drugs and other crimes after it was discovered he had passed off the drug to its producer Qiqihar No. 2 Pharmaceutical as a normal ingredient of the drug. (Click here for more
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.